Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CABIBBO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.810
EU - Europa 6.729
AS - Asia 6.356
SA - Sud America 1.078
Continente sconosciuto - Info sul continente non disponibili 951
AF - Africa 209
OC - Oceania 16
AN - Antartide 1
Totale 29.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.387
SG - Singapore 2.241
RU - Federazione Russa 1.924
IT - Italia 1.623
CN - Cina 1.494
BR - Brasile 819
HK - Hong Kong 671
DE - Germania 600
VN - Vietnam 598
FI - Finlandia 569
BD - Bangladesh 471
PL - Polonia 455
FR - Francia 313
GB - Regno Unito 309
UA - Ucraina 276
CA - Canada 233
JP - Giappone 201
IE - Irlanda 189
IN - India 136
KR - Corea 120
SE - Svezia 94
AR - Argentina 86
NL - Olanda 83
CI - Costa d'Avorio 62
MX - Messico 61
RO - Romania 58
IQ - Iraq 56
TR - Turchia 54
ES - Italia 49
EC - Ecuador 48
AT - Austria 47
ZA - Sudafrica 39
CO - Colombia 38
ID - Indonesia 37
BE - Belgio 35
CR - Costa Rica 28
SA - Arabia Saudita 28
PK - Pakistan 27
UZ - Uzbekistan 25
JM - Giamaica 24
MY - Malesia 24
PH - Filippine 24
PY - Paraguay 24
MA - Marocco 22
VE - Venezuela 22
KE - Kenya 21
EG - Egitto 20
CH - Svizzera 14
IR - Iran 14
LT - Lituania 14
AU - Australia 13
AZ - Azerbaigian 13
JO - Giordania 13
AE - Emirati Arabi Uniti 12
CL - Cile 12
GT - Guatemala 12
NI - Nicaragua 12
PE - Perù 11
TH - Thailandia 11
TN - Tunisia 11
BO - Bolivia 10
IL - Israele 10
KZ - Kazakistan 10
NP - Nepal 10
PS - Palestinian Territory 10
TW - Taiwan 10
BG - Bulgaria 9
DK - Danimarca 9
HN - Honduras 9
DZ - Algeria 8
LB - Libano 8
SV - El Salvador 8
AL - Albania 7
OM - Oman 7
BY - Bielorussia 6
CZ - Repubblica Ceca 6
EE - Estonia 6
MD - Moldavia 6
PA - Panama 6
RS - Serbia 6
SC - Seychelles 6
SN - Senegal 6
UY - Uruguay 6
GE - Georgia 5
AO - Angola 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
EU - Europa 4
GR - Grecia 4
LV - Lettonia 4
TT - Trinidad e Tobago 4
BS - Bahamas 3
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
PT - Portogallo 3
TG - Togo 3
XK - ???statistics.table.value.countryCode.XK??? 3
AF - Afghanistan, Repubblica islamica di 2
BA - Bosnia-Erzegovina 2
Totale 28.164
Salva come PNG Salva come JPEG
Città #
Ashburn 1.614
Singapore 1.512
San Jose 1.312
Fairfield 1.137
Chandler 723
Hong Kong 643
Woodbridge 557
Houston 461
Seattle 440
Wilmington 409
Zgierz 385
Cambridge 380
Moscow 333
Council Bluffs 332
Ann Arbor 304
Los Angeles 279
New York 278
Palermo 254
Beijing 230
Ho Chi Minh City 211
Santa Clara 194
Tokyo 194
Medford 192
Dallas 190
Dublin 187
Lauterbourg 178
Helsinki 162
Altamura 161
Hanoi 157
Jacksonville 144
Boardman 142
Hefei 131
Buffalo 116
Princeton 116
Frankfurt am Main 114
Lawrence 109
Milan 102
Nanjing 101
Rome 97
Des Moines 89
São Paulo 85
The Dalles 78
Toronto 78
Chicago 76
San Diego 69
London 68
Orem 66
Phoenix 64
Abidjan 62
Jinan 58
Atlanta 51
Warsaw 51
Montreal 50
Brooklyn 49
Lappeenranta 49
Nuremberg 49
Venice 48
Dearborn 45
Denver 45
Ludwigshafen am Rhein 44
Shenyang 44
Columbus 39
Tulsa 39
San Francisco 37
Changsha 35
Brussels 34
Hebei 33
Haiphong 32
Tianjin 32
Nanchang 31
Poplar 31
Zhengzhou 31
Chennai 30
Da Nang 29
Turin 28
Amsterdam 26
Naples 26
Paris 26
Baghdad 24
Brasília 24
San José 24
Washington 24
Munich 23
Ningbo 23
Guangzhou 22
Hangzhou 22
Johannesburg 22
Stockholm 22
Bologna 21
Shanghai 21
Tashkent 21
Boston 20
Bremen 20
Kumar 20
Philadelphia 20
Rio de Janeiro 20
Saint Petersburg 20
Vienna 20
Curitiba 19
Jiaxing 19
Totale 16.909
Salva come PNG Salva come JPEG
Nome #
EASL position paper on clinical follow-up after HCV cure 359
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 351
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 311
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 290
Causes of and prevention strategies for hepatocellular carcinoma. 284
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 275
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 273
The cheating liver: imaging of focal steatosis and fatty sparing 268
L'impiego del Tachosil in chirurgia epatica 260
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 259
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 259
Assessment of treatment response in hepatocellular carcinoma: a review of literature 252
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part I - Cystic lesions 251
Computed tomography of bowel obstruction: Tricks of the trade 251
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 249
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 247
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 247
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 246
Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? 244
Treatment of hepatocellular carcinoma: present and future. 242
Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device-Initial observations. 238
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 238
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 236
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. 229
Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. 228
Minor hepatic resection using heat coagulative necrosis. 226
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 222
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 222
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma 221
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease 220
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid 219
"Should cirrhosis change our attitude towards treating non-hepatic cancer?" 217
Antiviral therapy in the palliative setting of HCC (BCLC-B and -C) 216
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 213
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. 212
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 211
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 211
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 211
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 209
Update on new approaches in the management of hepatocellular carcinoma. 209
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 209
Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist 208
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib 205
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 205
Treatment of hepatitis C: critical appraisal of the evidence 204
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center 203
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. 201
The changing scenario of hepatocellular carcinoma in Italy: an update 200
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 197
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. 194
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. 193
Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease 192
Sicurezza ed efficacia della chemioembolizzazione arteriosa transcatetere nel trattamento dei pazienti con epatocarcinoma: studio triennale di 75 pazienti italiani 190
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors' reply 189
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. 189
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. 189
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis 188
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. results from a prospective study 188
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 187
Imaging appearance of treated hepatocellular carcinoma. 186
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 186
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. 185
Prognostic scores for hepatocellular carcinoma: none is the winner. 183
Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing 183
Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance 181
L'impiego del Tissue-Link FB3.0 floating ball nelle resezioni epatiche 180
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial 177
Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase 176
Systemic therapies for hepatocellular carcinoma: The present and the future 176
Sorafenib for hepatocellular carcinoma: From randomized controlled trials to clinical practice 174
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 173
Extrahepatic spread of hepatocellular carcinoma 173
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 172
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 171
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 171
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 169
Multimodal approaches to the treatment of hepatocellular carcinoma. 166
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 164
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 164
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 160
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis 159
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 159
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 157
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 157
Seeding after radiofrequency thermal ablation of hepatocellular carcinoma in cirrhosis: a prospective study 156
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 150
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 150
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 149
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part II - Solid lesions 146
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? 146
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules 145
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 144
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 143
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort 142
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 141
Hepatocellular carcinoma with macrovascular invasion: Multimodality imaging features for the diagnosis 140
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 139
Epidemiology, risk factors and surveillance of hepatocellular carcinoma 135
Hepatitis B Virus-Associated Hepatocellular Carcinoma 131
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 130
Totale 20.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.098 0 0 0 36 31 61 57 110 211 134 199 259
2022/20232.251 205 446 39 218 242 297 100 156 373 51 93 31
2023/20241.015 44 140 49 69 71 280 105 60 24 26 42 105
2024/20253.242 85 183 358 283 93 140 200 170 237 342 407 744
2025/202612.482 708 357 780 1.245 1.077 1.717 1.580 1.328 996 1.122 734 838
2026/20272.652 635 609 1.335 73 0 0 0 0 0 0 0 0
Totale 29.150